Pulnovo Medical Announces First Enrollment in Singapore for Global Clinical Study of PADN Technology in Treating Pulmonary Hypertension Associated with Left Heart Disease
SHANGHAI, Aug. 9, 2024 /PRNewswire/ -- Pulnovo Medical Limited,a globally recognized device pioneer in the treatment of Pulmonary Hypertension (PH) and Heart Failure (HF), is pleased to announce the launch of Asia's first international multi-center clinical study of Percutaneous Pulmonary Artery Denervation (PADN) for the treatment of PH associated with left heart disease. This exciting event took place at...
Innovative Anti-Nausea Smartwatch EmeTerm® Smart Set to Launch on Indiegogo
VANCOUVER, BC, Aug. 8, 2024 /PRNewswire/ -- EmeTerm® Smart uses patented hybrid technology to seamlessly integrate the functionality of a smartwatch with that of an anti-nausea wristband, ensuring a carefree and healthy life for all. EmeTerm® Smart is launching on Indiegogo as the world's first anti-nausea smart watch. EmeTerm® Smart's story...
T-MAXIMUM PHARMACEUTICAL Announces Latest Clinical Advances in Allogeneic CAR-T Cell Therapy Breakthrough for Solid Tumors
Summary T-Maximum Pharmaceutical develops allogeneic CAR-T therapies with a unique CRISPR/Cas9 Gene-Editing platform for solid tumors, provide a solution of two major pain points, GvHD and HvG, aiming to revolutionize cancer. MT027, the product of target B7H3 received US FDA orphan drug designation (ODD) on 2023 and will engage IND of US FDA in Q1 2025. As of...
MALAYSIA HEALTHCARE TRAVEL COUNCIL (MHTC) CONTINUES TO ENHANCE AND ELEVATE THEIR “EXPERIENCE MALAYSIA HEALTHCARE (EMH) STORIES” SERIES WITH EPISODE 3
KUALA LUMPUR, Malaysia, Aug. 8, 2024 /PRNewswire/ -- Malaysia Healthcare Travel Council (MHTC) continues their ongoing efforts to enhance and elevate their "Experience Malaysia Healthcare (EMH) Stories" with the third episode featuring Prof. Dato Sri Dr. Alwi Mohamed Yunus from Institut Jantung Negara (IJN). In this episode, Dr. Alwi shares with viewers his...
WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers
Partnership leverages Medigene's leadership for T cell receptor (TCR) generation and characterization and WuXi Biologics' unique anti-CD3 mAb, its T cell engager (TCE) platform and proprietary bispecific antibody platform WuXiBody™ Collaboration is a three-year and potentially multi-TCR program partnership SHANGHAI and MUNICH, Aug. 8, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development...
WestGene to Advance Clinical Trials Following Dual IND Approvals for World’s First EB Virus-Related mRNA Therapeutic Cancer Vaccine
CHENGDU, China, Aug. 8, 2024 /PRNewswire/ -- WestGene Biopharma is proud to announce that its mRNA therapeutic cancer vaccine, WGc-043, has received dual IND approvals from China's National Medical Products Administration (NMPA) and the US FDA. This unprecedented achievement marks the world's first IND-approved mRNA vaccine for EBV-related cancers in both the United States and China. ...
Morinaga Nutritional Foods Vietnam Promoting Sustainable Development with Advanced Technology, Unique functional ingredient, and Green Production
HANOI, Vietnam, Aug. 8, 2024 /PRNewswire/ -- Morinaga Nutritional Foods Vietnam (MNFV), an integral part of Morinaga Milk Industry Group - one of the leading company in the dairy and nutrition industry in Japan renowned for over a century of innovation and quality - embodies a commitment to excellence. By leveraging Morinaga Milk's extensive experience, advanced technology, MNFV is uniquely positioned to...
Fierce Competition and Technological Innovation Drive Diabetes Care Devices Market Towards Explosive Growth
OEMs Leading the Charge with AI-Equipped Technology and Novel Business Strategies SAN ANTONIO, Aug. 8, 2024 /PRNewswire/ -- The diabetes care devices industry is witnessing a dynamic evolution, marked by intense competition among established players and emerging start-ups. Original Equipment Manufacturers (OEMs) are at the forefront, introducing innovative, AI-equipped technology designed to improve patient outcomes and enhance diabetes care....
PeproMene Bio announced study demonstrating strong polyfunctionality of novel chimeric antigen receptor (CAR) T cells
Polyfunctionality correlates with a patient's remission lasting over 18 months with the CAR T cell therapy IRVINE, Calif., Aug. 7, 2024 /PRNewswire/ -- PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies for cancers and immune disorders, today announced that City of Hope-developed BAFF-R CAR T, known as PMB-CT01, demonstrated better...
Concord Medical Regains Compliance with NYSE Minimum Price Requirement
BEIJING, Aug. 7, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it has received a letter from the New York Stock Exchange ("NYSE") dated August 6, 2024 (the "Compliance Notice"), notifying the Company that it is no...
